Intraperitoneal autologous gamma/delta T cell therapy for refractory gastric cancer with ascites.

Intraperitoneal autologous gamma/delta T cell therapy for refractory gastric cancer with ascites. - Autologous gamma/delta T cell therapy for gastric cancer with ascites.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004130

Enrollment

Registered

2010-08-30

Start date

2010-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary gastric adenocarcinoma

Interventions

Zoledronic acid hydrate is administered on day-1, 6, 13, 20 and autologous gamma/delta T cells are intraperitoneally injected on day0, day7, day14, day21.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Primary gastric adenocarcinoma patients who meet the following: - Resistant to standard therapies or rejection of them; - Peritoneal dissemination and capable of removing ascites in safety; - Performance status is 0-2; - No serious abnormality in heart, lung, bone marrow, liver, and renal functions.

Exclusion criteria

Exclusion criteria: Patients who have: - Pulmonary fibrosis or interstitial pneumonia, including their history or predisposition; - Active enteritis and/or gastrointestinal bleeding; - Active autoimmune diseases; - Active infections; - Other cancers; - Brain metastasis; - Continuous systemic administration of steroids.

Design outcomes

Primary

Measure	Time frame
Safety : Adverse events	—

Secondary

Measure	Time frame
Pharmacokinetics Overall survival Progression-free survival Immunological responses	—

Countries

Japan

Contacts

Public ContactKazuhiro Kakimi

The University of Tokyo, Graduate School of Medicine Department of Immunotherapeutics

immunotherapy-admin@umin.ac.jp03-5805-3161

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026